Experimental stem cells offered to kids with rare COVID complication
Disease control
NO_LONGER_AVAILABLE
This study provides early access to an experimental stem cell treatment called remestemcel-L for children aged 2 months to 17 years with MIS-C, a severe inflammatory condition linked to COVID-19. The treatment aims to calm the immune system and reduce inflammation. Participants r…
Sponsor: Mesoblast International Sàrl • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC